Company
Interius BioTherapeutics
- Business model
- B2B
Record updated 28 September 2026
About
Acquired by Kite, a Gilead company, for $350M. Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.
Company
Record updated 28 September 2026
Acquired by Kite, a Gilead company, for $350M. Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.
A first look at Interius BioTherapeutics’s connections in the VC Catalog database. Sign in with Google to open the interactive map.
Investor VC firms in this preview
VC firm names are a sample from VC Catalog’s database and may be incomplete. A database connection is not a guarantee of an introduction.